Literature DB >> 7677476

Repair of complete atrioventricular canal defects: results with the two-patch technique.

C L Backer1, C Mavroudis, E T Alboliras, V R Zales.   

Abstract

BACKGROUND: Between 1983 and 1994, 115 infants and children underwent repair of a complete atrioventricular canal defect with the two-patch technique and routine mitral valve "cleft" closure.
METHODS: A retrospective review of these 115 patients was performed. Age at the time of repair ranged from 1 month to 108 months (mean age, 14.2 +/- 16.5 months; median age, 8 months). Preoperative cardiac catheterization in 113 patients revealed a mean pulmonary to systemic flow ratio of 3.37 +/- 1.8, a mean pulmonary artery systolic pressure of 71.1 +/- 15.7 mm Hg, and a mean pulmonary vascular resistance of 4.9 +/- 3.3 units. Associated anomalies included Down's syndrome (99 patients), patent ductus arteriosus (47), and coarctation of the aorta (4). Rastelli classification was A (76 patients), B (10), C (24), and unknown (5). Twenty-four patients had intraoperative epicardial or transesophageal echocardiography.
RESULTS: Although there was a trend toward increasing mean preoperative pulmonary vascular resistance with age from 2.1 +/- 0.9 units (0 to 3 months) to 4.0 +/- 2.6 units (4 to 6 months) to 5.7 +/- 3.0 units (7 to 12 months), the mean pulmonary vascular resistance of each age group was not significantly different from that of the main group. The operative survival rate was 94% (seven early deaths) and the overall survival rate, 91% (three late deaths). Intraoperative echocardiography altered the surgical therapy for 1 patient. No patient has required reoperation for a residual ventricular septal defect. Four patients (3.5%) had heart block requiring permanent pacemakers. Eight patients (7%) required reoperation for mitral insufficiency; 6 of whom had successful repair of a residual cleft.
CONCLUSIONS: For infants with complete atrioventricular canal defect, repair using the two-patch technique with routine mitral valve cleft closure at 4 to 6 months of age results in a low operative mortality, a low incidence of permanent heart block, and a low reoperation rate for mitral insufficiency.

Entities:  

Mesh:

Year:  1995        PMID: 7677476     DOI: 10.1016/0003-4975(95)00468-Z

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  7 in total

1.  Atrioventricular Canal Defects.

Authors:  D J Murphy
Journal:  Curr Treat Options Cardiovasc Med       Date:  1999-12

2.  The effect of changing attitudes to Down's syndrome in the management of complete atrioventricular septal defects.

Authors:  K Amark; J Sunnegårdh
Journal:  Arch Dis Child       Date:  1999-08       Impact factor: 3.791

3.  Traditional single patch versus the "Australian" technique for repair of complete atrioventricular canal defects.

Authors:  Velit Halit; Gursel Levent Oktar; Veli Yildirim Imren; Erkan Iriz; Dilek Erer; Serdar Kula; Fatma Sedef Tunaoglu; Levent Gokgoz; Rana Olgunturk
Journal:  Surg Today       Date:  2008-10-29       Impact factor: 2.549

4.  Post-operative left atrioventricular valve function after the staged repair of complete atrioventricular septal defect with tetralogy of Fallot.

Authors:  Kazuki Morimoto; Takaya Hoashi; Koji Kagisaki; Kenichi Kurosaki; Isao Shiraishi; Hajime Ichikawa
Journal:  Gen Thorac Cardiovasc Surg       Date:  2014-05-07

5.  The modified single patch technique.

Authors:  Ralph S Mosca; Jan M Quaegebeur
Journal:  Ann Pediatr Cardiol       Date:  2009-01

6.  Acquired left atrial-to-right ventricular shunt with mitral valve incompetence: a rare sequela after repair of atrioventricular septal defect.

Authors:  Srikant Mohapatra; Harpreet Singh Minhas; Sanjula Virmani; Bana Bihari Mishra; Kaushik Mukherjee; Amit Banerjee
Journal:  Tex Heart Inst J       Date:  2009

7.  Complete versus partial atrioventricular canal: equal risks of repair in the modern era.

Authors:  Jeffrey T Cope; Gregory D Fraser; Peter C Kouretas; Irving L Kron
Journal:  Ann Surg       Date:  2002-10       Impact factor: 12.969

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.